ClinicalTrials.gov recorded primary completion on 21 July 2026 for a Phase 3 trial of orforglipron in participants with moderate-to-severe obstructive sleep apnea and overweight or obesity. The completed master protocol enrolled 712 participants and evaluated orforglipron against placebo.
Background
The study evaluated orforglipron in people with obstructive sleep apnea and overweight or obesity. Its master protocol supported two independent studies, GZ01 and GZ02, with participants assigned to the appropriate study before randomization. GZ01 included participants who were unable or unwilling to use positive airway pressure therapy, while GZ02 included participants using positive airway pressure therapy for at least three months at screening and planning to continue it during the study.
Trial design
This Phase 3 study, identified as NCT06649045, was listed as completed and enrolled 712 participants. The conditions were obstructive sleep apnea and overweight or obesity. The listed interventions were orforglipron and placebo. The protocol evaluated efficacy and safety across the two independent studies within the master protocol.
What this means
The registry record documents completion of a large late-stage clinical study of orforglipron in participants with obstructive sleep apnea and overweight or obesity. It distinguishes between participants not using positive airway pressure therapy and those continuing established therapy. The supplied record contains no primary-outcome entries, outcome measurements, statistical analyses, or adverse-event summary, so it does not provide evidence about the treatment’s efficacy, safety, or comparative results.
Source
Source: ClinicalTrials.gov, clinical trial registry record for “A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight,” dated 21 July 2026. Available at clinicaltrials.gov/study/NCT06649045.